Norepinephrine precursor therapy in neurogenic orthostatic hypotension

Circulation

Volumn 108, Issue 6, 2003, Pages 724-728

  Kaufmann, Horacio ^a   Saadia, Daniela ^a   Voustianiouk, Andrei ^a   Goldstein, David S ^b   Holmes, Courtney ^b   Yahr, Melvin D ^a   Nardin, Rachel ^c   Freeman, Roy ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Blood pressure; Nervous system, autonomic; Norepinephrine; Receptors, adrenergic, alpha; Vasoconstriction

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA; NORADRENALIN; PLACEBO; THREO 3,4 DIHYDROXYPHENYLSERINE;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECARBOXYLATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; ORTHOSTATIC HYPOTENSION; PRESSOR RESPONSE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; STANDING; SUPINE POSITION;

ADMINISTRATION, ORAL; AGED; ANTIPARKINSON AGENTS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BLOOD PRESSURE; CARBIDOPA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DROXIDOPA; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NOREPINEPHRINE; POSTURE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0042663999     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000083721.49847.D7     Document Type: Article

References (23)

1. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med, 1969;280:337-345.
2. Kaufmann H. Could treatment with DOPS do for autonomic failure what DOPA did for Parkinson's disease? Neurology. 1996;47:1370-1371.
3. Biaggioni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in Oopamine-beta-hydroxylase deficiency. Lancet. 1987;2:1170-1172.
4. Man in't Veld AJ, Boomsma F, van den Meiracker AH, et al. Effect of unnatural noradrenaline precurser on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. Lancet. 1987;2:1172-1175.
5. Hoeldtke RD, Cilmi KM, Mattis-Graves K. DL-Threo-3, 4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension. Clin Pharmacol Ther. 1984;36:302-306.
6. Kaufmann H, Oribe E, Yahr MD. Differential effect of L-threo-3, 4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure. J Neural Transm Park Dis Dement Sect. 1991;3:143-148.
7. Freeman R, Landsberg L. The treatment of orthostatic hypotension with dihydroxyphenylserine. Clin Neuropharm. 1991;14:296-304.
8. Yanagisawa N, Ikeda S, Hashimoto T, et al. Effects of L-threo-Dops on orthostatic hypotension in Parkinson's disease [in Japanese]. No To Shinkei. 1998;50:157-163.
9. Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology. 1999;53:2151-2157.
10. Mathias CJ, Senard JM, Braune S, et al. L-Threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11:235-242.
11. Freeman R, Young J, Landsberg L, et al. The treatment of postprandial hypotension in autonomic failure with 3,4-DL-threo-dihydroxyphenylserine. Neurology. 1996;47:1414-1420.
12. Inagaki C, Fujiwara H, Tanaka C. Inhibitory effect of (+)threo-3, 4-dihydroxy-phenylserine (DOPS) on decarboxylation of (-)threo-dops. Jpn J Pharmacol. 1976;26:380-382.
13. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy: American Autonomic Society and American Academy of Neurology. Clin Auton Res. 1998;8:359-362.
14. Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res. 1996;6:125-126.
15. Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 1994;653:131-138.
16. Ichinose H, Sumi-Ichinose C, Ohye T, et al. Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase. Biochemistry. 1992;31:11546-11550.
17. Kato T, Karai N, Katsuyama M, et al. Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain: comparison with that of L-dopa. Biochem Pharmacol. 1987;36:3051-3057.
18. Kachi T, Iwase S, Mano T, et al. Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology. 1988;38:1091-1094.
19. Goldstein DS, Holmes C, Cannon RO, et al. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med. 1997;336:696-702.
20. Freeman R. Pure autonomic failure. In: Robertson D, ed. Disorders of the Autonomic Nervous System. Luxembourg: Harwood Academic Publishers; 1995:83-106.
21. Hague K, Lento P, Morgello S, et al. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol (Berl). 1997;94:192-196.
22. Polinsky RJ, Kopin IJ, Ebert MH, et al. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology. 1981;31:1-7.
23. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277:1046-1051.